Abstract 364P
Background
To develop artificial intelligence auto-segmentation model that generates consistent, high-quality lymph nodes contouring in head and neck cancer patients who received radiotherapy.
Methods
There were 60 computed tomography (CT) scans were retrospectively selected into training and another 60 CT scans were collected into cross-validation. All target delineations covered head and neck lymph node level I through V and based on the Radiation Therapy Oncology Group (RTOG) guideline. All targets were approved by radiation oncologists specializing in head and neck cancer. The volume of interest and all approved contours were used to train a 3D U-Net model. Different lymph node levels were trained independently. The trained model was used on cross-validation group. Auto-segmentations were revised by 2 radiation oncologists.
Results
The Dice Similarity Coefficients were 0.79 and 0.88 in trained group and cross-validation group. The volume changes ranged from -22.2 to 89.0 cm3. The center shift for x-direction, y-direction, and z-direction were -0.57 to 0.16 cm, -0.14 to 0.88 cm, and -0.19 to 0.38 cm, respectively.
Conclusions
We developed an artificial intelligence auto-segmentation model to autodelineate head and neck lymph nodes. Most results of auto-segmentations were acceptable after radiation oncologist review. This enables more efficient and consistent targeting of neck lymph nodes in radiation treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract